← Back to Search
Effective Adoptive Immunotherapy Of Triple-negative Breast Cancer By Folate Receptor-alpha Redirected CAR T Cells Is Influenced By Surface Antigen Expression Level
De-Gang Song, Q. Ye, M. Poussin, J. Chacon, M. Figini, D. Powell
Published 2016 · Medicine
Download PDFAnalyze on Scholarcy
BackgroundThe poor prognosis and the limited efficacy of targeted therapy in patients with triple-negative breast cancer (TNBC) have raised the need for alternative therapies. Recent studies have demonstrated that folate receptor-alpha (FRα) may represent an ideal tumor-associated marker for immunotherapy for TNBC.MethodsThe aim of the present study was to apply a chimeric antigen receptor (CAR) approach for the targeting of FRα expressed on TNBC cells and evaluate the antitumor activity of CAR-engineered T cells in vitro and in vivo.ResultsWe found that human T cells expressing a FRα-specific CAR were potent and specific killers of TNBC cells that express moderate levels of FRα in vitro and significantly inhibited tumor outgrowth following infusion into immunodeficient mice bearing an MDA-MB-231 tumor xenograft. However, the antitumor activity of the FRα CAR T cells was modest when compared to the same CAR T cells applied in an ovarian tumor xenograft model where FRα expression is more abundant. Notably, FRα CAR T cells induced superior tumor regression in vivo against MDA-MB-231 that was engineered for overexpression of FRα.ConclusionsTaken together, our results show that FRα CAR T cells can mediate antitumor activity against established TNBC tumor, particularly when FRα is expressed at higher levels. These results have significant implications for the pre-selection of patients with high antigen expression levels when utilizing CAR-based adoptive T cell therapies of cancer in future clinical trials.
This paper references
Immune selection after antigen-specific immunotherapy of melanoma.
A. Riker (1999)
Folate receptor α: A storied past and promising future in immunotherapy
G. Clifton (2011)
In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB).
De-Gang Song (2011)
Activation-induced expression of CD137 permits detection, isolation, and expansion of the full repertoire of CD8+ T cells responding to antigen without requiring knowledge of epitope specificities.
M. Wolfl (2007)
Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies
D. T. Rodgers (2016)
Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients
D. Tan (2007)
Folate receptor alpha (FRA) expression in breast cancer: identification of a new molecular subtype and association with triple negative disease
D. J. O'Shannessy (2012)
Paradoxical Impact of Two Folate Receptors, FRα and RFC, in Ovarian Cancer: Effect on Cell Proliferation, Invasion and Clinical Outcome
Michelle K. Y. Siu (2012)
Chimeric antigen receptor-modified T cells for acute lymphoid leukemia.
S. Grupp (2013)
Galectin-3 mediates bone marrow microenvironment-induced drug resistance in acute leukemia cells via Wnt/β-catenin signaling pathway
Kaimin Hu (2015)
Enhancement of folate receptor alpha expression in tumor cells through the glucocorticoid receptor: a promising means to improved tumor detection and targeting.
T. Tran (2005)
Triple-negative breast cancer: therapeutic options.
S. Cleator (2007)
Computer-assisted coloring and illuminating based on a region-tree structure
R. Nascimento (2012)
Farletuzumab, a Humanized Monoclonal Antibody against Folate Receptor α, in Epithelial Ovarian Cancer: a Phase I Study
J. Konner (2010)
Folate-targeted therapies for cancer.
W. Xia (2010)
Folate receptor α associated with triple-negative breast cancer and poor prognosis.
Zhang Zhang (2014)
T-cell immunity to the folate receptor alpha is prevalent in women with breast or ovarian cancer.
K. Knutson (2006)
Farletuzumab in lung cancer.
A. Thomas (2013)
Conversion of murine antibodies to human antibodies and their optimization for ovarian cancer therapy targeted to the folate receptor
M. Figini (2008)
Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia
J. Wu (2015)
Multicenter Trial of EC145 in Advanced, Folate-Receptor Positive Adenocarcinoma of the Lung
M. Edelman (2012)
Bispecific antibodies and their applications
Gaowei Fan (2015)
A sensitivity scale for targeting T cells with chimeric antigen receptors (CARs) and bispecific T-cell Engagers (BiTEs)
J. D. Stone (2012)
CD27 costimulation augments the survival and antitumor activity of redirected human T cells in vivo.
De-Gang Song (2012)
Triple-negative breast cancer.
Debra L Winkeljohn (2008)
Folate binding protein and the estrogen receptor in breast cancer.
H. Rochman (1985)
Folate receptor overexpression is associated with poor outcome in breast cancer
L. Hartmann (2007)
CD28 and Inducible Costimulatory Protein Src Homology 2 Binding Domains Show Distinct Regulation of Phosphatidylinositol 3-Kinase, Bcl-xL, and IL-2 Expression in Primary Human CD4 T Lymphocytes 1
R. Parry (2003)
Remote control of therapeutic T cells through a small molecule–gated chimeric receptor
Chia-Yung Wu (2015)
Kinetics of tumor destruction by chimeric antigen receptor-modified T cells.
U. Anurathapan (2014)
Modulation of the folate receptor alpha gene by the estrogen receptor: mechanism and implications in tumor targeting.
K. M. Kelley (2003)
Chimeric antigen receptor T cells for sustained remissions in leukemia.
Shannon L Maude (2014)
Redirected antitumor activity of primary human lymphocytes transduced with a fully human anti-mesothelin chimeric receptor.
E. Lanitis (2012)
Chimeric Antigen Receptor T Cells with Dissociated Signaling Domains Exhibit Focused Antitumor Activity with Reduced Potential for Toxicity In Vivo
E. Lanitis (2013)
Mesothelin, a novel immunotherapy target for triple negative breast cancer
J. Tchou (2012)
Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo.
Michael C Milone (2009)
Folate Receptor-α (FOLR1) Expression and Function in Triple Negative Tumors
B. Necela (2015)
This paper is referenced by
Combination of Oncolytic Virotherapy and CAR T/NK Cell Therapy for the Treatment of Cancer
G. Kochneva (2020)
Preclinical Evaluation of Bispecific Adaptor Molecule Controlled Folate Receptor CAR-T Cell Therapy With Special Focus on Pediatric Malignancies
Y. Lu (2019)
Immunomodulation in hepatocellular cancer.
S. Lee (2018)
CAR T-cell therapy for triple-negative breast cancer: Where we are.
Yuetao Xie (2020)
Combinatorial delivery of superparamagnetic iron oxide nanoparticles (γFe2O3) and doxorubicin using folate conjugated redox sensitive multiblock polymeric nanocarriers for enhancing the chemotherapeutic efficacy in cancer cells.
Chetan Nehate (2017)
Anti-Folate Receptor Alpha–Directed Antibody Therapies Restrict the Growth of Triple-negative Breast Cancer
A. Cheung (2018)
A long way to the battlefront: CAR T cell therapy against solid cancers
Zhicai Wang (2019)
Chimeric antigen receptor T cells: a novel therapy for solid tumors
S. Yu (2017)
Folate-targeted immunotherapies: Passive and active strategies for cancer.
Batoul Farran (2019)
Clinical Implications of Folate Transport in the Central Nervous System.
Camille Alam (2020)
Safety, immunogenicity, and clinical efficacy of durvalumab in combination with folate receptor alpha vaccine TPIV200 in patients with advanced ovarian cancer: a phase II trial
D. Zamarin (2020)
Recent advances with cyclin-dependent kinase inhibitors: therapeutic agents for breast cancer and their role in immuno-oncology
G. Di Sante (2019)
Anti-Trop2 antibody-conjugated bioreducible nanoparticles for targeted triple negative breast cancer therapy.
Soyoung Son (2018)
Natural Killer Cell as Effectors in Chimeric Antigen Receptor Based Immunotherapies for Cancer
Richard T. Hogg (2019)
The Third Generation Anti-HER2 Chimeric Antigen Receptor Mouse T Cells Alone or Together With Anti-PD1 Antibody Inhibits the Growth of Mouse Breast Tumor Cells Expressing HER2 in vitro and in Immune Competent Mice
Panyuan Li (2020)
Clinical Trials of CART Cells in China
B. Liu (2019)
Folate receptor-&agr; expression in triple-negative and non-triple-negative invasive breast carcinoma
R. Salem (2017)
Radiation dosimetry of 18F-AzaFol: A first in-human use of a folate receptor PET tracer
S. Gnesin (2020)
EGFR‐targeted CAR‐T cells are potent and specific in suppressing triple‐negative breast cancer both in vitro and in vivo
Lin Xia (2020)
Antibody Conjugated Nanoparticles for Targeting Metastatic Triple Negative Breast Cancer
Vidhi Khanna (2016)
Driving CARs on the uneven road of antigen heterogeneity in solid tumors.
Nan Chen (2018)
Chimeric antigen receptor (CAR) T-cell immunotherapy for MUC1-positive breast cancer
A. Gavriil (2018)
Immunological therapy: A novel thriving area for triple-negative breast cancer treatment.
Xiangyu Wang (2019)
Immunotherapy in Triple-Negative Breast Cancer: Present and Future
Isaac Kim (2019)
Control of triple-negative breast cancer using ex vivo self-enriched, costimulated NKG2D CAR T cells
Yali Han (2018)
Folate receptor alpha expression associates with improved disease-free survival in triple negative breast cancer patients
N. Norton (2020)
Clinical trials of CAR-T cells in China
Bingshan Liu (2017)
The Obesity Paradox in Cancer, Tumor Immunology, and Immunotherapy: Potential Therapeutic Implications in Triple Negative Breast Cancer
A. Naik (2019)
Advances on immunotherapy in breast cancer
Kanthi Athreya (2017)
Immunotherapy for the treatment of breast cancer
M. M. Moreno Ayala (2017)
CAR-T Cells and Oncolytic Viruses: Joining Forces to Overcome the Solid Tumor Challenge
S. Guedan (2018)
CD215+ Myeloid Cells Respond to Interleukin 15 Stimulation and Promote Tumor Progression
Shouheng Lin (2017)See more